Dr. Eran Eden, PhD
Co-founder and CEO, Board of Directors
Eran has been the CEO of MeMed since its inception in 2009, leading it from an idea to a rapidly growing company. He has 15 years of combined business and academic experience pioneering the development of cutting-edge multidisciplinary technologies that synergize data-science & machine learning, molecular biology and clinical applications. Eran co-founded several highly funded international consortia (e.g., Tailored-Treatment and Respiratory-ImmunoDx), the mission of which is to develop, clinically validate and commercialize novel technologies for diagnosing patients with infectious diseases and inflammatory disorders. He holds a B.Sc. in Computer Engineering, B.A. in Biology, and M.Sc. in Computer Science (all Cum Laude) from the Technion, Israel Institute of Technology, and a Ph.D. in Systems Biology from the Weizmann Institute of Science, where he was also a lecturer of Data Mining. Eran is co-author of over 90 granted patents and pending applications and over 20 peer-reviewed publications and is the recipient of multiple awards including the prestigious GE and Science Prize for Promising Life Scientists.
Dr. Kfir Oved, PhD
Co-Founder, CTO and Chairman of Board of Directors
Kfir has over 15 years of combined industry and academic experience, leading interdisciplinary and multicultural teams combining Applied Immunology, Biochemistry, Engineering, Big Data, and Industrial Design, in multiple clinical applications. Kfir co-founded MeMed Dx and serves as its CTO and Chairman of the Board, where he led the development and clinical validation of the entire MeMed technology suite including the MeMed BV™ technology, and the MeMed Key™ Point of care platform, from an initial concept to development completion. He holds a B.A. in Biology (Summa Cum Laude), B.Sc. in Medicine (Magna Cum Laude), Ph.D. in Molecular Immunology, and 6 years training at the Technion-Institute of Technology School of Medicine. He is the co-author of 83 granted and pending patents, the author of 16 peer-reviewed publications, and the recipient of multiple research excellence awards, including the prestigious Gutwirth Excellence award and the Wolf Award for research students, and was listed as one of the top 25 voices in Precision Medicine for 2019.
Chief Operating Officer
Idan has over 15 years of leadership experience in international operations and supply chain, lean manufacturing and service in the pharmaceutical and medical device industries. Prior to joining MeMed’s team, Idan led the global operations, supply chain and service as COO for Degania Medical, a world leader for disposable catheters, cardiovascular catheters and custom procedure trays, with 6 manufacturing plants and 3 logistics sites globally. Prior to that, Idan led the operations of the Israeli and Canadian sites as VP Operations for Taro Pharmaceuticals (NYSE: TARO), a multinational manufacturer of OTC and Rx oral solid dosage, semi-solid and liquid formulations. Idan holds a B.Sc. in Biotechnology and Food Engineering from the Technion – Israel Institute of Technology, and an MBA from Haifa University.
Dr. Frederic Sweeney, PhD
Chief Business Development Officer
Fred has extensive experience in the healthcare industry with senior leadership roles leading strategy and corporate development in both small and large organizations. Prior to joining MeMed, Fred served a dual role of Entrepreneur-In-Residence for Versant Ventures, a global venture capital firm, and Chief Business Officer of Northern Biologics, a developer of first-in-class immuno-oncology products. Prior to this, Fred served as Vice President of Corporate Development and Head of Strategic Financing at bioMérieux, a world leader in in-vitro diagnostic, where he led all aspects of the company strategic investments and partnerships. Before joining bioMérieux, Fred was Head of Business Development and Strategy at T2 Biosystems. During his tenure with the company, T2 Biosystems grew from a small venture-backed startup to a revenue-stage, Nasdaq-listed company that received FDA approval for blood tests that identify sepsis-causing pathogens without the wait for blood culture. A graduate of the Molecular and Medical Genetics Department and Terry Fox Scholar at the University of Toronto, Fred completed a Ph.D. focused on DNA repair, signal transduction and structural biology. He is also an adjunct professor at the University of Toronto, where he teaches a graduate level course on entrepreneurship in life sciences.
Dr. Tanya Gottlieb, PhD
VP of Scientific Affairs
Tanya has over 20 years of experience in academia and biotech, specializing in building and cultivating international collaborations and securing non-dilutive financing. Before joining MeMed, Tanya was Director of Business Development at BiondVax Pharmaceuticals Ltd (NASDAQ: BVXV), an innovative start-up developing a universal flu vaccine, where she initiated collaborations with the National Institute of Health (US) and European Commission. Prior to that, Tanya served as an independent consultant for key opinion leaders in Israel and Europe, helping to maximize their impact in the field and win awards. Tanya conducted her postdoctoral research at the Weizmann Institute of Science, Israel and the Fred Hutchinson Cancer Research Center in Seattle, WA, USA. Tanya holds a B.A. in Natural Sciences and Ph.D. from Cambridge University, UK. and an MBA from the Technion, Israel. She is the co-author of over 20 peer reviewed publications and the recipient of multiple awards, including the prestigious Royal Society (UK)-Israel Academy Fellowship.
VP Commercial and Corporate Development
Ofer has over 15 years of experience in global operations, business development, strategic planning and M&As. Prior to joining MeMed, Ofer led the global operations of MediaMind Technologies Inc. Prior to that, he was the COO of Neuronix Medical, a medical device company in the field of Alzheimer’s treatment. Before that, Ofer acted as VP of Business Development & Legal Counsel for Office Depot (Israel) and served as commercial lawyer for prominent Israeli law firms. Ofer holds an LLB from the Hebrew University and an MBA (Finance) from the Interdisciplinary Center in Herzliya.
Dr. Efrat Hartog-David, PhD
Director of Regulatory Affairs and Quality Assurance
Efrat has over a decade of experience in Quality Assurance, Clinical and Regulatory Affairs. She has managed product lifecycle quality and regulatory submissions for clearances of numerous medical devices in the US, EU, China, and rest of the world. Before joining MeMed, Efrat was Regulatory Affairs Manager at GE Healthcare, responsible for leading and executing the global regulatory strategy for the Nuclear Medicine business. As part of her role at GE Healthcare she led a team responsible for providing leadership and guidance on global compliance, developing global regulatory strategies and plans, and preparing regulatory submissions and worldwide registrations. Efrat has also served as Regulatory Affairs specialist at Philips Healthcare, where she was the regulatory lead for programs aimed at introduction of new product, and played a key role in internal and external audits. Prior to that, Efrat served as a consultant for a wide range of medical device companies, focusing on clinical study design, quality system management, and regulatory strategy development and execution. Efrat holds a B.Sc. and Ph.D. in Biotechnology and Food Engineering from the Technion, Haifa, Israel.
Kfir has more than a decade experience in the fields of finance and accounting. Prior to joining MeMed’s team, Kfir, previously acted as the Financial Controller at Viola Ventures, Israel's leading VC firm with over $1.3 billion assets under management. Prior to that, Kfir held the position of senior auditor at PWC, specializing in auditing biotech companies. Kfir has extensive experience in private placements, cash management, strategic planning, deal analysis, accounting and financial operations management. Kfir is a Certified Public Accountant and also holds a B.A. in Accounting and Economics and an MBA (Financial Management), both from the Tel Aviv University.
Hila has over 18 years of experience in senior HR leadership roles with fast growing tech companies at various stages. Prior to joining MeMed Hila served as HR Business Partner for EMEA region at Amdocs (NASDAQ: DOX), and for the Operation Innovation Unit where she oversaw all global HR activities. Prior to that Hila worked with startups (e.g. Flash Networks and Correlsense) and was responsible for the global human resources strategy. Hila holds a B.A. in Social Work from Tel Aviv University and an MBA from Bar-Ilan University.
Adee has over 18 years of extensive experience in healthcare and high-tech industries, in executive marketing, commercial and financial roles, in global corporates, local subsidiaries and entrepreneurial ventures. She previously served in marketing and commercial leadership roles at Teva Pharmaceuticals Ltd (NASDAQ: TEVA), as the head of marketing and business Initiatives, generics business, Chief of Staff to the President and CEO, EMIA & APAC and CFO, APAC & China, successfully leading commercialization of numerous medical devices, generic drugs and innovative solutions. Before her tenure at Teva, Adee served in various financial senior roles in high tech global corporates. Adee brings vast experience in market entries, product launch, building and developing growth strategies in complex global environments. Adee earned her Bachelor of Science in Economy and Corporate communications and her executive MBA (Magna cum laude), both from the Hebrew university of Jerusalem.
Dr. Vered Behar, PhD
Vered has extensive experience in the biotech industry, both in Pharma and medical devices, specializing in early- and mid-stages of product development. In her last position she served as the Chief Science Officer in an oncology clinical stage pharma company (Vidac Pharma). Prior to that, Vered served as the Vice President of Biology at Dynamix Pharmaceuticals, focusing on the discovery and development of targeted small molecule drugs for cancer and auto-immune therapies. Before Dynamix, she served as the Chief Scientist for Quantomix, which developed a high-resolution imaging tool to analyze native biological samples such as white blood cells and biopsies. Vered holds a B.Sc. and M.Sc. in Chemistry and an MBA from the Hebrew University, and a Ph.D. in Medical Sciences from Harvard University. Her post-doctoral training was at Wyeth (now Pfizer). She is the co-author of over 20 peer-reviewed publications and the recipient of multiple awards, including the prestigious Ryan Fellowship at Harvard University.
Dr. Oren Zarchin, PhD
Oren is a highly experienced leader of Product Development in global corporations, with more than 20 years of business and academic experience in the medical and semiconductors industries. In his latest role, Oren served as VP Product Development and executive management at Mazor Robotics LTD. Following Mazor's acquisition by Medtronic PLC. he served as VP Product development at Medtronic, leading R&D and Product Management. Prior to Medtronic Oren held various leadership positions at Philips Healthcare where he led multi-disciplinary R&D teams and product platforms in the US and Israel. Oren has a Ph.D. in Physics from the Weizmann institute of Science, M.Sc. (summa cum laude) in Physics and B.Sc. (cum laude) in Computer Science and Physics from Tel-Aviv University. He holds 15 patents and is the co-author on multiple publications.